Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Tirapazamine (Primary)
- Indications Carcinoma; Liver cancer; Liver metastases; Neuroendocrine tumours; Solid tumours
- Focus Adverse reactions
- Sponsors Teclison
- 09 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.
- 09 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2018 Planned number of patients changed from 33 to 63.